The FDA approval of a new drug is often treated as the end of the story. In reality, approval marks the beginning of a new chapter of safety and effectiveness monitoring that continues for as long as the drug is on the market.
Phase IV: Post-Marketing Studies
Approval is based on trial data from typically a few thousand patients studied over months to a few years. After approval, the drug is prescribed to millions of patients over years and decades. Phase IV extends the evidence base:
Spontaneous reporting: Healthcare providers and patients report adverse events through the FDA’s MedWatch system.
Registries: Long-term patient registries track outcomes in large real-world populations, often capturing rare adverse events not visible in trials.
Post-marketing commitment studies: The FDA frequently requires sponsors to conduct specific post-approval studies as a condition of approval, particularly for drugs approved under accelerated or breakthrough pathways.
How Post-Market Data Can Change a Drug’s Status
New post-market safety signals can result in: – Label changes (new warnings, contraindications, dosing adjustments) – Risk evaluation and mitigation strategies (REMS), restricted prescribing programs – Voluntary or FDA-mandated withdrawal
Why Clinical Trial Participation Still Matters After Approval
Clinical trials continue after approval for: – New indications (using an approved drug for different conditions) – New populations (pediatric extensions, geriatric-specific studies) – Combination regimens – Comparative effectiveness, how the new drug performs vs. existing options in real-world conditions